Showing 1431-1440 of 3105 results for "".
Stroke Snapshot: Cerebral Microinfarcts—Etiology and Clinical Implications of This Novel MRI Marker
https://practicalneurology.com/diseases-diagnoses/stroke/stroke-snapshot-cerebral-microinfarcts-etiology-and-clinical-implications-of-this-novel-mri-marker/32105/Cerebral microinfarcts—microscopic brain lesions of ischemic origin—have been linked to cerebral small vessel disease, microemboli, cerebral hypoperfusion, cognitive decline, and poor clinical outcome.Headache Attributed to Spontaneous Intracranial Hypotension
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-attributed-to-spontaneous-intracranial-hypotension/31769/Spontaneous intracranial hypotension (SIH) is often underdiagnosed; when cerebrospinal fluid leak is present, epidural blood patches are effective.Clinical Biomarker Testing for Alzheimer Disease Pathology in the Context of Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/clinical-biomarker-testing-for-alzheimer-disease-pathology-in-the-context-of-amyloid-targeting-treatments/67050/As blood-based biomarkers become integrated into routine practice, selecting the right test and understanding its limitations have become essential for accurate Alzheimer disease diagnosis and timely access to treatment.Quality of Life for Older People With Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/quality-of-life-for-older-people-with-epilepsy/32178/Focusing on all aspects of health and well-being when treating older adults with epilepsy is important for improving quality of life.Health Care Disparities in Alzheimer Disease Diagnosis and the Use of Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/health-care-disparities-in-alzheimer-disease-diagnosis-and-the-use-of-amyloid-targeting-treatments/36240/Disparities in Alzheimer disease care persist, and people from underrepresented racial, ethnic, or socioeconomic groups face considerable barriers to early diagnosis and access to disease-modifying anti-amyloid therapies.MS Minute: Oral Therapies for MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-oral-therapies-for-ms/31607/The advent of oral therapies has ushered in a new phase of disease-modifying treatments.Chronic Facial Weakness and Deafness
https://practicalneurology.com/diseases-diagnoses/stroke/chronic-facial-weakness-and-deafness/31104/A 66-year-old Indian man reported bilateral facial weakness that started when he was 15 to 20 years old and affected both upper and lower parts of the face. Two to three years later, he developed hoarseness and was found to have bilateral vocal cord paralysis, which required a tracheostomy several y- Editorial Board & Contributorshttps://practicalneurology.com/columns/practice-management/editorial-board-contributors/31089/The November 2007 issue of Practical Neurology features a distinguished editorial leadership and a diverse panel of contributors dedicated to advancing neurological medicine. Chief Medical Editor Dr. Stephen Gollomp, Chief of Neurology at Lankenau Hospital and Clinical Professor at Thomas Jefferson
- Medicare Audits: The “Fight is On”https://practicalneurology.com/columns/practice-management/medicare-audits-the-fight-is-on/31453/Navigating Evolving Medicare Audits: Strategies for Neurology PractitionersThe realm of Medicare auditing is becoming increasingly intricate, urging neurologists and other healthcare professionals to reassess their billing practices and compliance measures. Recent regulatory updates have transformed
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31258/Medicare’s projected 5.1% reimbursement cuts for 2007 have reignited concerns among neurologists and other medical specialists about significant financial strain. If these cuts proceed as planned, physicians could see their earnings reduced by up to 40% by 2015. These reductions highlight underlying